cep-37440
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2013 (NCT01922752)
Timeline
Indications
Mechanism of action
- Focal adhesion kinase 1INHIBITOR
PTK2 inhibitor
- ALK tyrosine kinase receptorINHIBITOR
ALK inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CNC(=O)c1ccccc1Nc1nc(Nc2ccc3c(c2OC)CCC[C@H](N2CCN(CCO)CC2)C3)ncc1Cl- Mol. weight
- 580.13 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3951811 ↗
- ChEMBLCHEMBL3545051 ↗
Also known as
- bms-986165
- bms-986165
- cep-37440
- cep-37440
- cep-37440
- cep-37440
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03044873 | Phase 1 | Feb 2, 2017 | Bristol-Myers Squibb |
| NCT03004768 | Phase 1 | Jan 1, 2017 | Bristol-Myers Squibb, Covance |
| NCT02931838 | Phase 2 | Nov 15, 2016 | Bristol-Myers Squibb |
| NCT02534636 | Phase 1 | Oct 1, 2015 | Bristol-Myers Squibb |
| NCT01922752 | Phase 1 | Jul 1, 2013 | Teva |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 4 | 4 | 2 | 2015 |
| Covance | For profit | 1 | 0 | 1 | 2017 |
| Teva | For profit | 1 | 1 | 1 | 2013 |
3 organizations
Page 1 / 1